Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ANRS EP69 BICTEVOIR : A Prospective Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing bictégravir, Emtricitabine and ténofovir alafénamide

NCT05222945 is registered in ClinicalTrials.gov with ANRS, Emerging Infectious Diseases as lead sponsor.

NCT NCT05222945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05222945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ANRS EP69 BICTEVOIR : A Prospective Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing bictégravir, Emtricitabine and ténofovir alafénamide
Lead sponsor
ANRS, Emerging Infectious Diseases
Phase
Not applicable
Overall status
Not yet recruiting
Start date
April 1, 2025
Completion date
October 31, 2025
Enrollment
34 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection